Drug intelligence / Profile preview

IOH-006

Development stage: Unknown
Lead developer: ImmuneOncia Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

IOH-006 is a bispecific antibody drug candidate developed by Immuneoncia Therapeutics. Its mechanism of action is as a CD47 inhibitor, targeting the CD47 protein (Cluster of Differentiation 47). By inhibiting CD47, which acts as a "don't eat me" signal on tumor cells, the drug aims to enhance immune-mediated clearance of cancer cells. As of April 2025, its highest development status is in the Discovery phase and there are no reported active or inactive clinical indications publicly disclosed[1].

Other names: IOH-006IOH006IOH 006

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on IOH-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IOH-006.

Explore the full profile